Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
Continued Positive Safety Data for OCU400 Established High Dose as the Maximum Tolerable Dose in…
News
BetterLife Announces Closing of Private Placement
VANCOUVER, British Columbia, Dec. 07, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Piiano Equips Developers to Stop Sensitive Data Breaches
Data protection company Piiano officially launches a vault for sensitive customer data, the first among…
RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments
Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA…
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
DMPK Transcript Levels Figure 1. No significant changes in mean DMPK transcript levels were observed…
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
BioVie Issues Letter to Shareholders
Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase…
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
Trem-cel (formerly VOR33) successfully manufactured and engrafted normally Blood counts successfully maintained following post-transplant treatment…
Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io
– Dante Genomics uses the 1health.io platform to accelerate their go to market strategy and…
Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
DURHAM, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) — Atsena Therapeutics, a clinical-stage gene therapy company…
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains…
Cronos Unveils its New CBC Product: Spinach FEELZ™ Day Trip Gummies With THC+CBC
Spinach FEELZ™ THC+CBC Day Trip Gummies Spinach FEELZ™ THC+CBC Day Trip Gummies TORONTO, Dec. 07,…
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission…
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1…
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including…
Castellum, Inc. Announces Insider Open-Market Stock Purchases
Castellum, Inc. Announces Insider Open-Market Stock Purchases Castellum, Inc.’s (the “Company”) (NYSE-American: CTM), Mark C….
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of…
Bazaarvoice Announces First-to-Market Revenue Attribution for Organic Facebook Posts
Tools will enable social media managers to track and optimize top performing posts to drive…
Coalesce Expands Leadership Team with Key Hires Across Departments
Data Transformations Startup Bolsters Team With Seasoned Hires Following Series A SAN FRANCISCO, Dec. 07,…